Krishna Polu

Krishna Polu, a nephrologist, serves as chief medical officer and is responsible for the translational and clinical strategy and execution for the Cytomx Probody™ programs. Throughout his career, he has had significant experience with drug development and regulatory interactions and approvals for biologics. Previously, Dr. Polu served as vice president and head of clinical development for Affymax. Prior to joining Affymax, Dr. Polu served as executive director, global development and in various clinical development leadership roles at Amgen, where he was responsible for late-stage clinical programs in nephrology, diabetes and heart failure. Before joining Amgen, Dr. Polu was a clinical and research fellow at Harvard Medical School in the renal division at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Polu has co-authored nine peer-reviewed publications and several book chapters. Dr. Polu earned a B.A. in human biology from Stanford University and an M.D. from University of Texas Health Science Center, San Antonio. He completed his residency training in internal medicine at the University of Colorado.